Specificity enhancing reagent for robust SARS-CoV-2 serology testing

作为COVID-19大流行应对措施的一部分，测量对SARS-CoV-2的免疫反应的存在将被广泛用于确定个体是否获得免疫。抗体与病毒蛋白上的特定位点结合。测量血浆和血清中可以结合SARS-CoV-2蛋白的抗体的存在，可以提供有关个体是否免疫的信息。这是在临床试验期间和上市后监测疫苗有效性的关键测试方法。挑战在于，引起普通感冒的普通冠状病毒在人群中广泛存在，并且与SARS-CoV-2具有相似的病毒蛋白质结构。这意味着，对于一些人来说，当他们进行免疫测试时，他们现有的针对常见冠状病毒蛋白的抗体可能会结合SARS-CoV-2蛋白，从而产生可测量的信号和错误的结果。这个人会被告知他们对SARS-CoV-2有免疫力，但他们没有免疫力，在日常活动中可能会面临更高的风险。最终，这将导致更高的可避免感染率和相关住院率，并产生更广泛的经济和社会影响。Apis Assay Technologies Ltd.旨在开发一种新颖的创新试剂，以阻止普通冠状病毒抗体结合SARS-CoV-2病毒蛋白。这意味着结合SARS-CoV-2蛋白的抗体产生的任何可测量信号都将是由于SARS-CoV-2抗体的存在，因此大大降低了错误结果的可能性。这种创新试剂有潜力以高投资回报应对一个庞大的全球疫苗监测市场。Apis Assay Technologies Ltd.计划推出两款商业产品——**1)**一种独立试剂，可用于调整和提高任何兼容的第三方免疫测试的性能；**2)**是一种具有高度竞争性的免疫试验。为了最大限度地渗透市场，api化验技术有限公司努力快速跟踪产品开发，以促进这些产品的早期使用。

As part of the COVID-19 pandemic response, measuring the presence of an immune response to SARS-CoV-2 will be widely used to determine whether individuals have acquired immunity. Antibodies bind to specific sites on viral proteins. Measuring the presence of antibodies that can bind SARS-CoV-2 proteins in the plasma and serum can provide information about whether an individual is immune. This is a critical testing approach for monitoring the effectiveness of vaccines during clinical trials and after launch.The challenge is that common coronaviruses that cause the common cold are widespread in the population and have similar viral protein structures to SARS-CoV-2\. This means that for some individuals, when they are tested for immunity, their existing antibodies against common coronavirus proteins may bind SARS-CoV-2 proteins, generating a measurable signal and an incorrect result. This individual will be told that they have immunity against SARS-CoV-2 when they are not immune and may expose themselves to a higher risk in their daily activities. Ultimately, this will lead to a higher rate of avoidable infections and associated hospitalisations, with wider economic and social impacts.Apis Assay Technologies Ltd. aims to develop a novel, innovative reagent to block common coronavirus antibodies from binding SARS-CoV-2 viral protein. This means that any measurable signal generated from antibodies binding SARS-CoV-2 proteins will be due to the presence of SARS-CoV-2 antibodies, therefore drastically reducing the likelihood of an incorrect result. This innovative reagent has potential to address a large global vaccine monitoring market with high return on investment. Apis Assay Technologies Ltd. plans two commercial product launches - **1)** a stand-alone reagent that can be used to adapt and improve performance of any compatible 3rd party immunity test; **2)** a highly competitive immunity test with the reagent integrated. For maximum penetration of the market, Apis Assay Technologies Ltd. strives to fast-track product development to facilitate early access to these products.